Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2006 pubmed

Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS.

Fernie-King. B A BA; Seilly. D J DJ; Lachmann. P J PJ

Key Findings

  • SIC protein from virulent GAS strains blocks LL‑37 and other antimicrobial peptides
  • The N‑terminal SRR plus the long repeat region (LRR) of SIC are required for LL‑37 inhibition
  • A related protein, DRS, also inhibits LL‑37 but lacks the LRR and does not affect lysozyme or complement

Practical Outcomes

  • The main takeaway is that strep infections can undermine your natural LL‑37 defenses, so preventing or promptly treating these infections is important. There’s no direct protocol change for LL‑37 supplementation, but supporting overall immune health and avoiding severe GAS infections remains key.

Summary

Some especially nasty group A strep bacteria make proteins (SIC and DRS) that can neutralize LL‑37, a natural antimicrobial peptide your body uses to fight infections, along with several other immune proteins. This means that during a strep infection, the bacteria can blunt part of your innate defense.

Abstract

SIC (streptococcal inhibitor of complement) is a 31 kDa protein secreted by a few highly virulent strains of GAS (group A streptococci), predominantly by the M1 strain. Initially described as an inhibitor of the membrane attack complex of complement, it has turned out to be a polyfunctional inhibitor of the innate mucosal immune response. The SIC protein sequence contains three domains: an N-terminal SRR (short repeat region), followed by three longer tandem repeats [LRR (long repeat region)] and a C-terminal PRR (proline-rich region). SIC inhibits the antibacterial activity of a wide range of antimicrobial peptides and proteins: i.e. lysozyme, SLPI (secretory leucocyte proteinase inhibitor), LL-37, hNP-1 (human neutrophil peptide-1) and the human beta-defensins 1, 2 and 3. Analysis of the functional properties of recombinant domains of SIC shows that binding and inhibition of lysozyme and human beta-defensin-3 require the SRR+LRR, as does binding to SLPI. Complement inhibition is confined to the SRR. M12 GAS secrete a protein 'distantly related to SIC' (DRS). DRS contains a C-terminal PRR which is significantly similar to that of SIC, but it has no central LRR and the N-terminal SRR is very different. DRS inhibits human beta-defensin-3, but has no effect on lysozyme, SLPI or complement.

Study Information

Provider

pubmed

Year

2006

DOI

10.1042/bst20060273